View Item 

Show simple item record

Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation
dc.contributor.authorToubai, T.en_US
dc.contributor.authorShono, Y.en_US
dc.contributor.authorNishihira, J.en_US
dc.contributor.authorIbata, M.en_US
dc.contributor.authorSuigita, J.en_US
dc.contributor.authorKato, N.en_US
dc.contributor.authorOhkawara, T.en_US
dc.contributor.authorTone, S.en_US
dc.contributor.authorLowler, Kathleen P.en_US
dc.contributor.authorOta, S.en_US
dc.contributor.authorTanaka, J.en_US
dc.contributor.authorAsaka, M.en_US
dc.contributor.authorReddy, P.en_US
dc.contributor.authorImamura, M.en_US
dc.date.accessioned2010-06-01T18:59:17Z
dc.date.available2010-06-01T18:59:17Z
dc.date.issued2009-04en_US
dc.identifier.citationTOUBAI, T.; SHONO, Y.; NISHIHIRA, J.; IBATA, M.; SUIGITA, J.; KATO, N.; OHKAWARA, T.; TONE, S.; LOWLER, K. P.; OTA, S.; TANAKA, J.; ASAKA, M.; REDDY, P.; IMAMURA, M. (2009). "Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation." International Journal of Laboratory Hematology 31(2): 161-168. <http://hdl.handle.net/2027.42/72178>en_US
dc.identifier.issn1751-5521en_US
dc.identifier.issn1751-553Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72178
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18081874&dopt=citationen_US
dc.format.extent208065 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation © 2009 Blackwell Publishing Ltden_US
dc.subject.otherMacrophage Migration Inhibitory Factoren_US
dc.subject.otherAcute Graft-versus-Host-diseaseen_US
dc.subject.otherChronic Graft-versus-Host-diseaseen_US
dc.subject.otherAllogeneic Stem Cell Transplantationen_US
dc.titleSerum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantationen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumBlood and marrow stem cell transplantation program, University of Michigan Cancer Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother* Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japanen_US
dc.contributor.affiliationotherDepartment of Research and Development, GeneticLab Co. Ltd, Sapporo, Japanen_US
dc.contributor.affiliationotherDepartment of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japanen_US
dc.identifier.pmid18081874en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72178/1/j.1751-553X.2007.01016.x.pdf
dc.identifier.doi10.1111/j.1751-553X.2007.01016.xen_US
dc.identifier.sourceInternational Journal of Laboratory Hematologyen_US
dc.identifier.citedreferenceAsif Amin M., Haas C.H., Zhu K., Mansfield P.J., Kim M.J., Lackowski N.P. & Koch A.E. ( 2006 ) Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 linase, and NFkB. Blood 107, 2252 – 2261.en_US
dc.identifier.citedreferenceBacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., Gemsa D., Donnelly T. & Bucala R. ( 1996 ) An essential regulatory role for macrophage migration inhibitory factor in T cell activation. Proceedings of the National Academy of Sciences of the United States of America 93, 7849 – 7854.en_US
dc.identifier.citedreferenceBaker K.S., Gurney J.G., Ness K.K., Bhatia R., Forman S.J., Francisco L., McGlave P.B., Robison L.L., Snyder D.S., Weisdorf D.J. & Bhatia S. ( 2004 ) Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 104, 1898 – 1906.en_US
dc.identifier.citedreferenceBernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., Manogue K.R., Cerami A. & Bucala R. ( 1993 ) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756 – 759.en_US
dc.identifier.citedreferenceBernhagen J., Bacher M., Calandra T., Metz C.N., Doty S.B., Donnelly T. & Bucala R. ( 1996 ) An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. The Journal of Experimental Medicine 183, 277 – 282.en_US
dc.identifier.citedreferenceBloom B.R. & Bennett B. ( 1966 ) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80 – 82.en_US
dc.identifier.citedreferenceBrown F.G., Nikolic-Paterson D.J., Metz C., Bucala R., Atkins R.C. & Lan H.Y. ( 1999 ) Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clinical and Experimental Immunology 118, 329 – 336.en_US
dc.identifier.citedreferenceBucala R. ( 1996 ) MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. The FASEB Journal 10, 1607 – 1613.en_US
dc.identifier.citedreferenceCalandra T., Bernhagen J., Mitchell R.A. & Bucala R. ( 1994 ) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. The Journal of Experimental Medicine 179, 1895 – 1902.en_US
dc.identifier.citedreferenceCalandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., Cerami A. & Bucala R. ( 1995 ) MIF as a glucocorticoid-induces modulator of cytokine production. Nature 377, 68 – 71.en_US
dc.identifier.citedreferenceDavid J.R. ( 1966 ) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences of the United States of America 56, 72 – 77.en_US
dc.identifier.citedreferenceDonnelly S.C., Haslett C., Reid P.T., Grant I.S., Wallace W.A., Metz C.N., Bruce L.J. & Bucala R. ( 1997 ) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine 3, 320 – 323.en_US
dc.identifier.citedreferenceFerrara J.L., Cooke K.R. & Teshima T. ( 2003 ) The pathophysiology of acute graft-versus-host disease. International Journal of Hematology 78, 181 – 187.en_US
dc.identifier.citedreferenceFerrara J.L. & Deeg H.J. ( 1991 ) Graft-versus-host disease. New England Journal of Medicine 324, 667 – 674.en_US
dc.identifier.citedreferenceGraze P.R. & Gale R.P. ( 1979 ) Chronic graft versus host disease: a syndrome of disordered immunity. The American Journal of Medicine 66, 611 – 620.en_US
dc.identifier.citedreferenceHill G.R. & Ferrara J.L. ( 2000 ) The primacy of the gastrointestinal tract as a target organ of acute graft-versus- host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95, 2754 – 2759.en_US
dc.identifier.citedreferencede Jong Y.P., Abadia-Molina A.C., Satoskar A.R., Clarke K., Rietdijk S.T., Faubion W.A., Mizoguchi E., Metz C.N., Alsahli M., ten Hove T., Keates A.C., Lubetsky J.B., Farrell R.J., Michetti P., van Deventer S.J., Lolis E., David J.R., Bhan A.K. & Terhorst C. ( 2001 ) Development of chronic colitis is dependent on the cytokine MIF. Nature Immunology 2, 1061 – 1066.en_US
dc.identifier.citedreferenceJose M.D., David J.R., Atkins R.C. & Chadban S.J. ( 2003 ) Blockade of macrophage migration inhibitory factor does not prevent acute renal allograft rejection. American Journal of Transplantation 3, 1099 – 1106.en_US
dc.identifier.citedreferenceLan H.Y., Bacher M., Yang N., Mu W., Nikolic-Paterson D.J., Metz C., Meinhardt A., Bucala R. & Atkins R.C. ( 1997 ) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. The Journal of Experimental Medicine 185, 1455 – 1465.en_US
dc.identifier.citedreferenceLan H.Y., Yang N., Brown F.G., Isbel N.M., Nikolic-Paterson D.J., Mu W., Metz C.N., Bacher M., Atkins R.C. & Bucala R. ( 1998 ) Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 66, 1465 – 1471.en_US
dc.identifier.citedreferenceLan H.Y., Yang N., Nikolic-Paterson D.J., Yu X.Q., Mu W., Isbel N.M., Metz C.N., Bucala R. & Atkins R.C. ( 2000 ) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney International 57, 499 – 509.en_US
dc.identifier.citedreferenceLo J.W., Leung A.Y., Huang X.R., Lie A.K., Metz C., Bucala R., Liang R. & Lan H.Y. ( 2002 ) Macrophage migration inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 30, 375 – 380.en_US
dc.identifier.citedreferenceMatsumoto K., Maruyama N., Maruyama T., Ohnishi Y., Nonaka S., Inoshita A., Ito K., Kitajima S., Abe M., Satomura A. & Fujita T. ( 2005 ) Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis. Clinical and Experimental Immunology 139, 338 – 347.en_US
dc.identifier.citedreferenceNishihira J. ( 2000 ) Macrophage migrataion inhibitory factor (MIF): its essential role in the immune system and cell growth. Journal of Interferon and Cytokine Research 20, 751 – 762.en_US
dc.identifier.citedreferenceOhkawara T., Nishihira J., Takeda H., Hige S., Kato M., Sugiyama T., Iwanaga T., Nakamura H., Mizue Y. & Asaka M. ( 2002 ) Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123, 256 – 270.en_US
dc.identifier.citedreferenceOnodera S., Tanji H., Suzuki K., Kaneda K., Mizue Y., Sagawa A. & Nishihira J. ( 1999 ) High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11, 163 – 167.en_US
dc.identifier.citedreferenceReddy P. & Ferrara J.L. ( 2003 ) Immunobiology of acute graft-versus-host disease. Blood Reviews 17, 187 – 194.en_US
dc.identifier.citedreferenceSelvi E., Tripodi S.A., Catenaccio M., Lorenzini S., Chindamo D., Manganelli S., Romagnoli R., Ietta F., Paulesu L., Miracco C., Cintorino M. & Marcolongo R. ( 2003 ) Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Annals of the Rheumatic Diseases 62, 460 – 464.en_US
dc.identifier.citedreferenceShlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., Shlomchik M.J. & Emerson S.G. ( 1999 ) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412 – 415.en_US
dc.identifier.citedreferenceShulman H.M., Sullivan K.M., Weiden P.L., McDonald G.B., Striker G.E., Sale G.E., Hackman R., Tsoi M.S., Storb R. & Thomas E.D. ( 1980 ) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. The American Journal of Medicine 69, 204 – 217.en_US
dc.identifier.citedreferenceSocie G., Stone J.V., Wingard J.R., Weisdorf D., Henslee-Downey P.J., Bredeson C., Cahn J.Y., Passweg J.R., Rowlings P.A., Schouten H.C., Kolb H.J. & Klein J.P. ( 1999 ) Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. New England Journal of Medicine 341, 14 – 21.en_US
dc.identifier.citedreferenceToubai T., Tanaka J., Nishihira J., Ohkawara T., Hirate D., Kondo N., Tone S., Shono Y., Ibata M., Sugita J., Kato N., Miura Y., Iwao N., Ota S. & Imamura M. ( 2006 ) Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation. Transplant immunology 16, 117 – 124.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1751-553X.2007.01016.x.pdf
Size:
203.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.